tiprankstipranks
Trending News
More News >
IRLAB Therapeutics AB Class A (SE:IRLAB.A)
:IRLAB.A
Sweden Market

IRLAB Therapeutics AB Class A (IRLAB.A) Financial Statements

Compare
0 Followers

IRLAB Therapeutics AB Class A Financial Overview

IRLAB Therapeutics AB Class A's market cap is currently kr366.71M. The company's EPS TTM is kr-1.602; its P/E ratio is ―; IRLAB Therapeutics AB Class A is scheduled to report earnings on ―, and the estimated EPS forecast is kr―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenuekr 94.63Mkr 5.68Mkr 61.14Mkr 207.78Mkr 300.00K
Gross Profitkr 94.63Mkr -122.73Mkr -111.23Mkr 168.69Mkr -1.70M
Operating Incomekr -75.11Mkr -180.76Mkr -113.11Mkr 52.58Mkr -91.46M
EBITDAkr -68.07Mkr -173.32Mkr -109.13Mkr 55.37Mkr -89.46M
Net Incomekr -83.13Mkr -177.84Mkr -114.20Mkr 51.78Mkr -91.85M
Balance Sheet
Cash & Short-Term Investmentskr 66.92Mkr 111.31Mkr 252.78Mkr 401.90Mkr 277.01M
Total Assetskr 136.21Mkr 177.12Mkr 323.56Mkr 472.45Mkr 370.07M
Total Debtkr 60.42Mkr 27.57Mkr 3.98Mkr 6.60Mkr 2.93M
Net Debtkr -6.50Mkr -83.74Mkr -248.80Mkr -395.30Mkr -274.08M
Total Liabilitieskr 103.58Mkr 61.36Mkr 32.72Mkr 72.97Mkr 22.19M
Stockholders' Equitykr 32.63Mkr 115.76Mkr 290.83Mkr 399.48Mkr 347.88M
Cash Flow
Free Cash Flowkr -65.79Mkr -165.14Mkr -145.99Mkr 127.93Mkr -89.61M
Operating Cash Flowkr -65.59Mkr -164.85Mkr -142.61Mkr 128.64Mkr -89.21M
Investing Cash Flowkr -199.00Kkr -293.00Kkr -3.38Mkr -708.00Kkr -394.00K
Financing Cash Flowkr 21.40Mkr 23.68Mkr -3.13Mkr -3.04Mkr 256.09M
Currency in SEK

IRLAB Therapeutics AB Class A Earnings and Revenue History

IRLAB Therapeutics AB Class A Debt to Assets

IRLAB Therapeutics AB Class A Cash Flow

IRLAB Therapeutics AB Class A Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis